GET DAILY SIGNALSBionano Genomics (BNGO) Q3 2026 Earnings: What the Numbers Could Reveal
Key Takeaways
- Bionano Genomics (NASDAQ: BNGO) is scheduled to report third quarter 2026 results after the market close on November 10, 2026, with a conference call at 4:30 p.m. ET.
- Consensus revenue estimates stand at approximately $8.44 million, while the company previously guided Q3 2026 revenue to a range of $8.2 million to $8.6 million, up 11% to 16% year over year.
- Analysts expect another net loss per share, with consensus estimates generally ranging between roughly -$0.45 and -$0.56, reflecting the company's continued pre-profitability stage.
- Investors will focus on nanochannel array flow cell sales, installed optical genome mapping (OGM) system counts, adjusted gross margin, and cash runway, which management cited as extending into at least early 2027.
- The company recently retired its senior secured convertible debt and secured reimbursement milestones, including a new Category I CPT code for constitutional genetic disorders.
Why This Report Matters for Bionano
Bionano Genomics provides optical genome mapping solutions for cytogenetics and clinical research and remains in a growth phase ahead of profitability. Its Q3 2026 results will show whether the company can maintain the double-digit revenue growth and strong margins seen in Q2 2026, when revenue increased 21% year over year to $8.2 million and adjusted gross margin hit a record 53%. With cash still tight and losses continuing, the report will indicate how quickly recurring consumable demand is building to support longer-term commercialization of its OGM and VIA software platforms. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Revenue and Loss Expectations
Heading into the release, the consensus revenue estimate sits near $8.44 million, close to the middle of management’s guidance range of $8.2 million to $8.6 million. That range points to year-over-year growth of about 11% to 16% from Q3 2025 revenue of roughly $7.37 million. Analysts anticipate another net loss, with per-share estimates between roughly -$0.45 and -$0.56, compared with a loss of about -$1.59 per share in the same quarter last year.
Outside the top-line numbers, attention will turn to nanochannel array flow cell sales as a gauge of consumable use at installed sites. In Q2 2026 the company sold a record 9,219 flow cells, up 27% year over year. Other areas of focus include the installed base of OGM systems, adjusted gross margin, adjusted operating expenses, and the cash and investments balance, which ended Q2 2026 at $10.4 million with a runway into at least the first quarter of 2027.
Market Sentiment and Recent Milestones
Sentiment ahead of the Q3 2026 print is measured, with some optimism offset by balance-sheet considerations. The stock has shown short-term volatility, and its smaller market capitalization can magnify moves after the release. On the positive side, Bionano has beaten consensus EPS estimates in six of the last eight quarters and achieved several milestones, such as retiring its senior secured convertible debt, securing a new Category I CPT code for constitutional genetic disorders, and seeing a 47% rise in payment determination for the CPT code tied to hematologic malignancy analysis. From what I see, these steps strengthen the reimbursement foundation over time.
Potential risks include manufacturing constraints and flow cell backorders, which have kept the upper end of guidance conservative. Investors will also assess whether the shift toward higher-margin consumables and software is improving profitability and whether cash burn stays within the expected runway.
Guidance, Reimbursement, and What Comes Next
After the report, attention will turn to whether Bionano reaffirms or updates its full-year 2026 revenue guidance of $31 million to $33 million. Management has noted that some large orders could move between quarters due to capacity limits, so any updates on clearing backlog will be important. Reimbursement progress remains a longer-term driver, though the speed at which new codes translate into revenue is still unclear.
Keeping adjusted gross margin near recent highs while managing operating expenses will matter for the goal of better profitability. Cash runway is another key point; with a modest balance, the company has indicated it may need additional financing and could face operational limits without it. Utilization metrics, publication trends, flow cell supply, and the VIA software rollout will serve as useful signals of adoption beyond any single quarter’s results. I’m watching this closely as these elements will likely shape the path ahead.
AI Tools in My Research Workflow
When preparing for earnings like this one, I often turn to Tickeron’s AI-powered tools to scan for comparable names and refine watchlists. The AI Screener stands out for its ability to apply technical patterns, fundamentals, and performance filters across thousands of stocks and ETFs. It helps surface ideas efficiently and compare candidates ahead of events such as earnings releases. For anyone following BNGO or similar small-cap growth stories, it offers a structured approach to organizing research without replacing fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BNGO's Indicator enters downward trend
The Aroon Indicator for BNGO entered a downward trend on November 09, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 321 similar instances where the Aroon Indicator formed such a pattern. In 290 of the 321 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
BNGO moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BNGO crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BNGO's RSI Indicator exited the oversold zone, 32 of 50 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 64%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 66 cases where BNGO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on BNGO as a result. In 68 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for BNGO just turned positive on November 09, 2026. Looking at past instances where BNGO's MACD turned positive, the stock continued to rise in 36 of 41 cases over the following month. The odds of a continued upward trend are 88%.
Following a +5.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNGO advanced for three days, in 165 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
BNGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.429) is normal, around the industry mean (4.964). P/E Ratio (-0.382) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.481) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. BNGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of technologies for analysis of large biological molecules
Industry PharmaceuticalsOther
Advertisement